Literature DB >> 8097428

Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

K Yoshida1, T Tachibana.   

Abstract

CD4+8- T lymphocytes with potent antitumor activity in vivo were obtained in peritoneal exudate cells by immunizing mice with irradiated MM48 tumor cells admixed with OK-432. These immune CD4+ T cells were used in adoptive immunotherapy for prevention of lymph node metastases after removal of the primary tumor. Complete cure of metastases was obtained by adoptive transfer of CD4+ T cells admixed with irradiated MM48 tumor cells, but not by CD4+ T cells alone. To analyze the curative effect of admixing tumor cells on the prevention of metastases, a model of 1-day tumor inoculated with macrophages was used. Administration of immune CD4+ T cells alone resulted in the regression of local tumor in more than half of the mice, although all of them eventually died of lymph node metastases. On the other hand, adoptive transfer of immune CD4+ T cells plus irradiated tumor cells resulted in the complete regression of local tumors in all the mice, which survived without any sign of metastasis. The curative effect of the immune CD4+ T cells obtained by admixing irradiated tumor cells was tumor-specific. Macrophages induced by OK-432 (tumoricidal), implanted together with tumor, assisted tumor regression more than did macrophages elicited by proteose peptone (non-tumoricidal) in the same adoptive transfer system. Administration of recombinant interleukin-2 instead of stimulant tumor cells did not enhance, but rather eliminated the constitutive antitumor activity of CD4+ T cells. On the other hand, exogenous recombinant interleukin-1 was more effective in the enhancement of antitumor activity of the CD4+ T cells as compared with stimulant tumor cell administration. In this case, the activating states of macrophages at the implanted tumor site had no influence on the therapeutic efficacy. A possible role of macrophages for induction of tumor-specific cytotoxic T cells that were mediated by tumor-specific CD4+ T cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097428     DOI: 10.1007/bf01741171

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.

Authors:  H Fujiwara; Y Takai; K Sakamoto; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

3.  Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes.

Authors:  M Saito; T Ebina; M Koi; T Yamaguchi; Y Kawade; N Ishida
Journal:  Cell Immunol       Date:  1982-03-15       Impact factor: 4.868

4.  Pretreatment of plastic Petri dishes with fetal calf serum. A simple method for macrophage isolation.

Authors:  K Kumagai; K Itoh; S Hinuma; M Tada
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

5.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.

Authors:  H Nakajima; H Fujiwara; Y Takai; Y Izumi; S Sano; T Tsuchida; T Hamaoka
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

6.  Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model.

Authors:  C S McCune; D M Marquis
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

7.  The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Authors:  H Fujiwara; M Fukuzawa; T Yoshioka; H Nakajima; T Hamaoka
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

8.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

9.  Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness.

Authors:  E A Kurt-Jones; S Hamberg; J Ohara; W E Paul; A K Abbas
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

10.  Cyclophosphamide-dependent lymph node modification in lymph node metastasis of MM48 tumor cells in syngeneic mice.

Authors:  K Yoshida; T Tachibana
Journal:  Jpn J Cancer Res       Date:  1990-03
View more
  1 in total

1.  Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma; an immunohistochemical study.

Authors:  J D Kerrebijn; A J Balm; P P Knegt; C A Meeuwis; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.